Clinical trial · Observational
PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Due to the generally poor prognosis, with no chance of long-term survival, health related quality of life is a very important objective in the treatment of patients with pancreatic cancer. The non-interventional, prospective, multicentre PARAGON study is desinged to evaluate the health-related quality of life in patients with metastatic pancreatic cancer, by analyzing the course of QoL throughout all applied therapy lines for patients with pancreatic adenocarcinoma, measured according to EORTC scoring manual and patient reported outcome.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Optional translational project | Other | — | UNRESOLVED |
| Quality of live questionnaires | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with pancreatic adenocarcinoma
- description
- Patients with metastatic pancreatic cancer receiving will be asked to fill in an EORTC QLQ-C30 questionnaire and additional questionnaires on worries about quality of life impairments and physical constitiution every 8 weeks, over the entire course of treatment, starting with neo-/adjuvant or 1st line therapy follow. There is no restriction on type of therapy. No further intervention.
- interventionNames
- Other: Quality of live questionnaires
- Other: Optional translational project
Primary outcomes (2)
- measure
- The course of Quality of Life (QoL) throughout the entire course of therapy for patients with pancreatic adenocarcinoma
- timeFrame
- through study completion, an average of 1 year
- description
- EORTC-QLQC30 according to EORTC scoring manual
- measure
- Other patient reported outcome (PRO)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Written informed consent and signed data protection form before any study specific intervention, including screening, will be done * Age ≥ 18 years * Histologically or cytologically confirmed pancreatic adenocarcinoma * Systemic neoadjuvant, adjuvant, 1st line systemic therapy is planned or recently started (within last 14 days) Exclusion Criteria: * Patients who are unable to consent because they do not understand the nature, significance and implications of the study * Patients who are unable to understand or fill out the QoL survey * Patients in 2nd or further treatment lines that have not been documented for 1st line therapy within the study
References
Publications (0)
Data not yet available